Frequent drug resistance seriously limits the therapeutic efficacy of sorafenib in advanced hepatocellular carcinoma (HCC).
Strategies to increase the response to sorafenib are limited, and the underlying mechanism to facilitate such an increase is not entirely understood.
Homeobox (HOX) transcript antisense intergenic RNA (
